Drug-induced osteoporosis: Mechanisms and clinical implications

American Journal of Medicine

Volumn 123, Issue 10, 2010, Pages 877-884

  Mazziotti, Gherardo ^a   Canalis, Ernesto ^b,c   Giustina, Andrea ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b SAINT FRANCIS HOSPITAL AND MEDICAL CENTER   (United States)

^c UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

Drugs; Fractures; Osteoporosis; Secondary osteoporosis

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALENDRONIC ACID; ANASTROZOLE; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIRETROVIRUS AGENT; AROMATASE INHIBITOR; BICALUTAMIDE; BISPHOSPHONIC ACID DERIVATIVE; BUDESONIDE; CALCINEURIN INHIBITOR; CORTICOSTEROID; DENOSUMAB; EXEMESTANE; GLUCOCORTICOID; GONADORELIN AGONIST; HEPARIN; LETROZOLE; LOOP DIURETIC AGENT; MEDROXYPROGESTERONE ACETATE; PARATHYROID HORMONE[1-34]; PREDNISONE; PROTON PUMP INHIBITOR; RISEDRONIC ACID; SEROTONIN UPTAKE INHIBITOR; TAMOXIFEN; THYROID HORMONE; THYROXINE; UNINDEXED DRUG; ZOLEDRONIC ACID; ANTIANDROGEN; GONADORELIN;

ANDROGEN DEPRIVATION THERAPY; AUTOIMMUNE DISEASE; BONE REMODELING; BREAST CANCER; CALCIUM METABOLISM; CARDIOVASCULAR DISEASE; CONGESTIVE HEART FAILURE; DEEP VEIN THROMBOSIS; DEPRESSION; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; ENDOMETRIOSIS; EPILEPSY; GASTROINTESTINAL DISEASE; GOITER; HIP FRACTURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOTHYROIDISM; IN VIVO STUDY; INFLAMMATORY DISEASE; LIVER DISEASE; MUSCULOSKELETAL DISEASE; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; THYROID CARCINOMA; VENOUS THROMBOEMBOLISM; VERTEBRA FRACTURE; AGONISTS; BONE DENSITY; CHEMICALLY INDUCED; DRUG EFFECTS; FEMALE; FRACTURES, BONE; MALE;

ANDROGEN ANTAGONISTS; ANTI-RETROVIRAL AGENTS; AROMATASE INHIBITORS; BONE DENSITY; CALCINEURIN; FEMALE; FRACTURES, BONE; GLUCOCORTICOIDS; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; OSTEOPOROSIS; THIAZOLIDINEDIONES; THYROXINE; CALCINEURIN INHIBITORS;

EID: 77957813220     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2010.02.028     Document Type: Review

References (75)

1. E. Canalis, G. Mazziotti, A. Giustina, and J.P. Bilezikian Glucocorticoid-induced osteoporosis: pathophysiology and therapy Osteoporos Int 18 2007 1319 1328
2. T.P. van Staa, H.G. Leufkens, and L. Abenhaim Use of oral corticosteroids and risk of fractures J Bone Miner Res 15 2000 993 1000 (Pubitemid 30350061)
3. A. Angeli, G. Guglielmi, and A. Dovio High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study Bone 39 2006 253 259
4. P. Vestergaard, L. Rejnmark, and L. Mosekilde Fracture risk associated with different types of oral corticosteroids and effect of termination of corticosteroids on the risk of fractures Calcif Tissue Int 82 2008 249 257
5. T.P. van Staa, R.F. Laan, and I.P. Barton Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy Arthritis Rheum 48 2003 3224 3229
6. J. Compston US and UK guidelines for glucocorticoid-induced osteoporosis: similarities and differences Curr Rheumatol Rep 6 2004 66 69
7. M. Doga, G. Mazziotti, and S. Bonadonna Prevention and treatment of glucocorticoid-induced osteoporosis J Endocrinol Invest 31 7 Suppl 2008 53 88
8. S. Amin, M.P. Lavalley, R.W. Simms, and D.T. Felson The comparative efficacy of drug therapies used for the management of corticosteroid-induced osteoporosis: a meta-regression J Bone Miner Res 17 2002 1512 1526
9. K.G. Saag, E. Shane, and S. Boonen Teriparatide or alendronate in glucocorticoid-induced osteoporosis N Engl J Med 357 2007 2028 2039
10. J.V. Parle, J.A. Franklyn, and K.W. Cross Thyroxine prescription in the community: serum thyroid stimulating hormone level assays as an indicator of undertreatment or overtreatment Br J Gen Pract 43 1993 107 109
11. B. Biondi, and D.S. Cooper The clinical significance of subclinical thyroid dysfunction Endocr Rev 29 2008 76 131
12. P. Lakatos Thyroid hormones: beneficial or deleterious for bone? Calcif Tissue Int 73 2003 205 209
13. G. Mazziotti, F. Sorvillo, and M. Piscopo Recombinant human TSH modulates in vivo C-telopeptides of type-1 collagen and bone alkaline phosphatase, but not osteoprotegerin production in postmenopausal women monitored for differentiated thyroid carcinoma J Bone Miner Res 20 2005 480 486
14. G. Mazziotti, T. Porcelli, I. Patelli, P.P. Vescovi, and A. Giustina Serum TSH values and risk of vertebral fractures in euthyroid post-menopausal women with low bone mineral density Bone 46 3 2010 747 751
15. M.C. Sheppard, R. Holder, and J.A. Franklyn Levothyroxine treatment and occurrence of fracture of the hip Arch Intern Med 162 2002 338 343
16. D.C. Bauer, B. Ettinger, M.C. Nevitt, and K.L. Stone Risk for fracture in women with low serum levels of thyroid-stimulating hormone Ann Intern Med 134 2001 561 568
17. A. Panico, G.A. Lupoli, and F. Fonderico Osteoporosis and thyrotropin-suppressive therapy: reduced effectiveness of alendronate Thyroid 19 2009 437 442
18. M. Rabaglio, Z. Sun, and K.N. Price Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial Ann Oncol 20 2009 1489 1498
19. M.N. Khan, and A.A. Khan Cancer treatment-related bone loss: a review and synthesis of the literature Curr Oncol 15 2008 S30 S40
20. C.B. Confavreux, A. Fontana, and J.P. Guastalla Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole Prevention with bisphosphonates Bone 41 2007 346 352
21. R.E. Coleman, L.M. Banks, and S.I. Girgis Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study Lancet Oncol 8 2007 119 127
22. A. Brufsky, N. Bundred, and R. Coleman Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole Oncologist 13 2008 503 514 (Pubitemid 351872868)
23. S.L. Greenspan, A. Brufsky, and B.C. Lembersky Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial J Clin Oncol 26 2008 2644 2652
24. M. Gnant, B. Mlineritsch, and W. Schippinger Endocrine therapy plus zoledronic acid in premenopausal breast cancer N Engl J Med 360 2009 679 691
25. G.K. Ellis, H.G. Bone, and R. Chlebowski Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer J Clin Oncol 26 2008 4875 4882
26. B.E. Hillner, J.N. Ingle, and R.T. Chlebowski American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer J Clin Oncol 21 2003 4042 4057
27. C.E. Cann Bone densitometry as an adjunct to GnRH agonist therapy J Reprod Med 43 1998 321 330
28. P. Vestergaard, L. Rejnmark, and L. Mosekilde The effects of depot medroxyprogesterone acetate and intrauterine device use on fracture risk in Danish women Contraception 78 2008 459 464
29. T. Cundy, J. Cornish, and M.C. Evans Recovery of bone density in women who stop using medroxyprogesterone acetate BMJ 308 1994 247 248
30. S.L. Greenspan, P. Coates, and S.M. Sereika Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer J Clin Endocrinol Metab 90 2005 6410 6417
31. H. Lee, K. McGovern, J.S. Finkelstein, and M.R. Smith Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma Cancer 104 2005 1633 1637
32. M.R. Smith, W.C. Lee, and J. Brandman Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer J Clin Oncol 23 2005 7897 7903
33. V.B. Shahinian, Y.F. Kuo, J.L. Freeman, and J.S. Goodwin Risk of fracture after androgen deprivation for prostate cancer N Engl J Med 352 2005 154 164
34. H.G. Ahlborg, N.D. Nguyen, and J.R. Center Incidence and risk factors for low trauma fractures in men with prostate cancer Bone 43 2008 556 560
35. S.L. Greenspan Approach to the prostate cancer patient with bone disease J Clin Endocrinol Metab 93 2008 2 7
36. A.E. Kearns, D.W. Northfelt, and A.C. Dueck Osteoporosis prevention in prostate cancer patients receiving androgen ablation therapy: placebo-controlled double-blind study of estradiol and risedronate: N01C8 Support Care Cancer 18 3 2010 321 328
37. J. Planas, E. Trilla, and C. Raventos Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis BJU Int 104 11 2009 1637 1640
38. M.R. Smith, M.A. Fallon, H. Lee, and J.S. Finkelstein Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial J Clin Endocrinol Metab 89 2004 3841 3846
39. M.R. Smith, S.B. Malkowicz, and F. Chu Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study J Clin Oncol 26 2008 1824 1829
40. M.R. Smith, B. Egerdie, and T.N. Hernandez Denosumab in men receiving androgen-deprivation therapy for prostate cancer N Engl J Med 361 2009 745 755
41. M.R. Smith, M. Goode, and A.L. Zietman Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition J Clin Oncol 22 2004 2546 2553
42. E. Canalis, A. Giustina, and J.P. Bilezikian Mechanisms of anabolic therapies for osteoporosis N Engl J Med 357 2007 905 916
43. A. Giustina, G. Mazziotti, and E. Canalis Growth hormone, insulin-like growth factors, and the skeleton Endocr Rev 29 2008 535 559
44. Y. Wan, L.W. Chong, and R.M. Evans PPAR-gamma regulates osteoclastogenesis in mice Nat Med 13 2007 1496 1503
45. S.E. Kahn, B. Zinman, and J.M. Lachin Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT) Diabetes Care 31 2008 845 851
46. T. Mancini, G. Mazziotti, and M. Doga Vertebral fractures in males with type 2 diabetes treated with rosiglitazone Bone 45 2009 784 788
47. Y.K. Loke, S. Singh, and C.D. Furberg Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis CMAJ 180 2009 32 39
48. V.K. Yadav, J.H. Ryu, and N. Suda Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum Cell 135 2008 825 837
49. J.B. Richards, A. Papaioannou, and J.D. Adachi Effect of selective serotonin reuptake inhibitors on the risk of fracture Arch Intern Med 167 2007 188 194
50. S.J. Petty, T.J. O'Brien, and J.D. Wark Anti-epileptic medication and bone health Osteoporos Int 18 2007 129 142
51. R. Rajgopal, M. Bear, M.K. Butcher, and S.G. Shaughnessy The effects of heparin and low molecular weight heparins on bone Thromb Res 122 2008 293 298
52. J.D. Douketis, J.S. Ginsberg, and R.F. Burrows The effects of long-term heparin therapy during pregnancy on bone density A prospective matched cohort study Thromb Haemost 75 1996 254 257
53. T.C. Dahlman Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin Am J Obstet Gynecol 168 1993 1265 1270
54. M. Monreal, E. Lafoz, and A. Olive Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin Thromb Haemost 71 1994 7 11
55. G. Matziolis, C. Perka, A. Disch, and H. Zippel Effects of fondaparinux compared with dalteparin, enoxaparin and unfractionated heparin on human osteoblasts Calcif Tissue Int 73 2003 370 379
56. P.A. Price, and M.K. Williamson Effects of warfarin on bone Studies on the vitamin K-dependent protein of rat bone J Biol Chem 256 1981 12754 12759
57. S.A. Jamal, W.S. Browner, D.C. Bauer, and S.R. Cummings Warfarin use and risk for osteoporosis in elderly women Study of Osteoporotic Fractures Research Group Ann Intern Med 128 1998 829 832
58. C. Woo, L.L. Chang, S.K. Ewing, and D.C. Bauer Single-point assessment of warfarin use and risk of osteoporosis in elderly men J Am Geriatr Soc 56 2008 1171 1176
59. D.S. van, S.R. Majumdar, and J.A. Bakal Heart failure is a risk factor for orthopedic fracture: a population-based analysis of 16,294 patients Circulation 118 2008 1946 1952
60. L. Rejnmark, P. Vestergaard, and L. Heickendorff Loop diuretics increase bone turnover and decrease BMD in osteopenic postmenopausal women: RESULTS: from a randomized controlled study with bumetanide J Bone Miner Res 21 2006 163 170
61. B. Abrahamsen, and K. Brixen Mapping the prescriptiome to fractures in mena national analysis of prescription history and fracture risk Osteoporos Int 20 2009 585 597
62. L.D. Carbone, K.C. Johnson, and A.J. Bush Loop diuretic use and fracture in postmenopausal women: findings from the Women's Health Initiative Arch Intern Med 169 2009 132 140
63. P. Orcel, M.A. Denne, and M.C. de Vernejoul Cyclosporin-A in vitro decreases bone resorption, osteoclast formation, and the fusion of cells of the monocyte-macrophage lineage Endocrinology 128 1991 1638 1646
64. C. Movsowitz, S. Epstein, and F. Ismail Cyclosporin A in the oophorectomized rat: unexpected severe bone resorption J Bone Miner Res 4 1989 393 398
65. G. Leidig-Bruckner, S. Hosch, and P. Dodidou Frequency and predictors of osteoporotic fractures after cardiac or liver transplantation: a follow-up study Lancet 357 2001 342 347
66. C.A. Kulak, V.Z. Borba, J.J. Kulak, and E. Shane Transplantation osteoporosis Arq Bras Endocrinol Metabol 50 2006 783 792
67. P.R. Ebeling Approach to the patient with transplantation-related bone loss J Clin Endocrinol Metab 94 2009 1483 1490
68. T.T. Brown, and R.B. Qaqish Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review AIDS 20 2006 2165 2174
69. V.A. Triant, T.T. Brown, H. Lee, and S.K. Grinspoon Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system J Clin Endocrinol Metab 93 2008 3499 3504
70. J. Huang, L. Meixner, S. Fernandez, and J.A. McCutchan A double-blinded, randomized controlled trial of zoledronate therapy for HIV-associated osteopenia and osteoporosis AIDS 23 2009 51 57
71. K. Mondy, W.G. Powderly, and S.A. Claxton Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection J Acquir Immune Defic Syndr 38 2005 426 431
72. J. Tuukkanen, and H.K. Vaananen Omeprazole, a specific inhibitor of H+-K+-ATPase, inhibits bone resorption in vitro Calcif Tissue Int 38 1986 123 125
73. Y.X. Yang, J.D. Lewis, S. Epstein, and D.C. Metz Long-term proton pump inhibitor therapy and risk of hip fracture JAMA 296 2006 2947 2953
74. C. Roux, K. Briot, and L. Gossec Increase in vertebral fracture risk in postmenopausal women using omeprazole Calcif Tissue Int 84 2009 13 19
75. P. Vestergaard, L. Rejnmark, and L. Mosekilde Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture Calcif Tissue Int 79 2006 76 83